Datapoint: FDA Approves GSK’s Jakafi Challenger

The FDA last week approved GSK’s JAK inhibitor Ojjaara (momelotinib) for broad use in intermediate or high-risk myelofibrosis, a rare blood cancer, in patients with anemia. GSK says it is the only approved myelofibrosis therapy available for both newly diagnosed and previously treated patients “that addresses the key manifestations of the disease, namely anaemia, constitutional symptoms and splenomegaly (enlarged spleen).” While Ojjaara is only available to anemic patients, it will still present a challenge to Incyte’s JAK powerhouse Jakafi (ruxolitinib) in the myelofibrosis market basket. Under the pharmacy benefit, Jakafi holds covered or better status as a myelofibrosis therapy for virtually all insured lives. About 16% of lives have preferred access to Jakafi, growing to 34% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 9/18/23

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 20

Datapoint: Ipsen’s Latest Accelerated Approval Will Challenge Intercept’s Ocaliva

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 18

Datapoint: Texas Won’t Halt Latest Medicaid Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 17

Datapoint: Oscar Plans to Double Enrollment by 2027

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today